{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:18:12Z","timestamp":1787894292597,"version":"build-2784847793"},"reference-count":43,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Pulmonary hypertension (PH) is an increasingly recognized complication of Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). Recent data suggest prognostic implications of both cardiovascular morbidity and mortality and hematologic progression. Additionally, PH and MPNs share common pathophysiologic mechanisms that bridge these two seemingly different disorders. The landscape of PH in MPNs is evolving in the face of improved survivorship and reduced disease progression, leading to increased incidence and prevalence of concurrent and\/or consequent cardiovascular disease. Prospective studies are necessary to refine screening protocols, risk stratification, and prognostic and therapeutic implications of PH in this population.<\/jats:p>","DOI":"10.3390\/cancers18172775","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:54:42Z","timestamp":1787763282000},"page":"2775","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Current Landscape of Pulmonary Hypertension in Myeloproliferative Neoplasms"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3701-4738","authenticated-orcid":false,"given":"Monica","family":"Ferrante","sequence":"first","affiliation":[{"name":"Gill Heart and Vascular Institute, University of Kentucky College of Medicine, Lexington, KY 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Ju","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Department of Hematology & Oncology, Mass General Brigham Cancer Institute, Massachusetts General Hospital & Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Leiva","sequence":"additional","affiliation":[{"name":"Gill Heart and Vascular Institute, University of Kentucky College of Medicine, Lexington, KY 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jaccao.2025.05.010","article-title":"Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients with Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review","volume":"7","author":"Leiva","year":"2025","journal-title":"JACC CardioOncol."},{"key":"ref_3","first-page":"2388","article-title":"Characterization and prognostic implication of pulmonary hypertension among patients with myeloproliferative neoplasms","volume":"110","author":"Leiva","year":"2025","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e017986","DOI":"10.1161\/CIRCIMAGING.124.017986","article-title":"Impact of Echocardiographic Probability of Pulmonary Hypertension on Prognosis and Outcomes Among Patients with Myeloproliferative Neoplasms","volume":"18","author":"Leiva","year":"2025","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.echo.2019.07.010","article-title":"Incremental Utility of Right Ventricular Dysfunction in Patients with Myeloproliferative Neoplasm\u2013Associated Pulmonary Hypertension","volume":"32","author":"Kim","year":"2019","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"A4372348","DOI":"10.1161\/circ.152.suppl_3.4372348","article-title":"Abstract 4372348: Characterization and Prognostic Implications of Pulmonary Hypertension on Right Heart Catheterization Among Patients with Myeloproliferative Neoplasms","volume":"152","author":"Leiva","year":"2025","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102561","DOI":"10.1016\/j.cpcardiol.2024.102561","article-title":"High output cardiac state: Evaluating the incidence, plausible etiologies and outcomes","volume":"49","author":"Bews","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_9","first-page":"52","article-title":"Echocardiographic high-output heart failure is associated with worse survival among patients with myelofibrosis","volume":"12","author":"Leiva","year":"2026","journal-title":"Cardiooncology"},{"key":"ref_10","first-page":"91","article-title":"Impact of echocardiographic hemodynamics on outcomes among patients with polycythemia vera or essential thrombocythemia","volume":"12","author":"Leiva","year":"2026","journal-title":"Cardiooncology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ejh.13543","article-title":"Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms","volume":"106","author":"Ferrari","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/bloodadvances.2024013970","article-title":"High pulmonary hypertension risk by echocardiogram shortens survival in polycythemia vera","volume":"9","author":"Gazda","year":"2025","journal-title":"Blood Adv."},{"key":"ref_13","first-page":"61","article-title":"Real-world prevalence and outcome of elevated right ventricular systolic pressure in myelofibrosis","volume":"12","author":"Sharma","year":"2026","journal-title":"Cardiooncology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1165\/rcmb.2019-0431OC","article-title":"Targeting Jak-Stat Signaling in Experimental Pulmonary Hypertension","volume":"64","author":"Yerabolu","year":"2021","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jacbts.2019.05.013","article-title":"JAK2 (V617F)-Mediated Clonal Hematopoiesis Accelerates Pathological Remodeling in Murine Heart Failure","volume":"4","author":"Sano","year":"2019","journal-title":"JACC Basic. Transl. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1038\/s41467-021-26435-0","article-title":"Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils","volume":"12","author":"Kimishima","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1093\/eurheartj\/ehab447","article-title":"The JAK-STAT pathway: An emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms","volume":"42","author":"Baldini","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_23","first-page":"166","article-title":"Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Leiva","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa2415160","article-title":"Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death","volume":"392","author":"Humbert","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the Treatment of Pulmonary Arterial Hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-021-01064-8","article-title":"Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice","volume":"14","author":"Minakawa","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Leiva, O., Soo, S., Liu, O.C., You, V., Palmer, A., Kahla, J., Murtaza, Y., Odenike, O., Patel, A., and DeCara, J. (2026). Risk factors associated with high probability of pulmonary hypertension in patients with myeloproliferative neoplasms. Int. J. Hematol.","DOI":"10.1007\/s12185-026-04255-6"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/rccm.202210-1941OC","article-title":"Clinical Phenotype and Outcomes of Pulmonary Hypertension Associated with Myeloproliferative Neoplasms: A Population-based Study","volume":"208","author":"Montani","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.echo.2025.01.006","article-title":"Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension: Recommendations from the American Society of Echocardiography","volume":"38","author":"Mukherjee","year":"2025","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_33","first-page":"443","article-title":"Group 5 Pulmonary Hypertension: The Orphan\u2019s Orphan Disease","volume":"34","author":"Kalantari","year":"2016","journal-title":"Cardiol. Clin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","article-title":"ACCF\/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10428194.2026.2639642","article-title":"Ruxolitinib and heart failure outcomes among patients with myelofibrosis","volume":"67","author":"Leiva","year":"2026","journal-title":"Leuk. Lymphoma"},{"key":"ref_36","first-page":"2660","article-title":"Sotatercept for anemia of myelofibrosis: A phase II investigator-initiated study","volume":"109","author":"Bose","year":"2024","journal-title":"Haematologica"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2018-11-876888","article-title":"Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis","volume":"133","author":"Fenaux","year":"2019","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/CIRCULATIONAHA.126.079918","article-title":"Sotatercept for Combined Post- and Precapillary Pulmonary Hypertension Associated with Heart Failure: Results From the Phase 2, Randomized, Placebo-Controlled CADENCE Study","volume":"153","author":"Tedford","year":"2026","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jaccao.2026.02.002","article-title":"Sotatercept for the Treatment of Myeloproliferative Neoplasm-Associated Group 5 Pulmonary Hypertension","volume":"8","author":"Ali","year":"2026","journal-title":"JACC CardioOncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00277-025-06334-w","article-title":"Transformed to myelofibrosis is a risk factor for pulmonary hypertension in Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"104","author":"Suolitiken","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12185-022-03454-1","article-title":"Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease","volume":"117","author":"Leiva","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41409-019-0741-8","article-title":"Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"55","author":"Gupta","year":"2020","journal-title":"Bone Marrow Transpl."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e1113","DOI":"10.1161\/CIR.0000000000001220","article-title":"Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the American Heart Association","volume":"149","author":"Hayek","year":"2024","journal-title":"Circulation"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2775\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:25:25Z","timestamp":1787891125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":43,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18172775"],"URL":"https:\/\/doi.org\/10.3390\/cancers18172775","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}